Literature DB >> 19708490

Diagnosis and prognosis of iatrogenic injury of the recurrent laryngeal nerve.

Jonas Hydman1, Gunnar Björck, Jonas K E Persson, Jan Zedenius, Per Mattsson.   

Abstract

OBJECTIVES: Following perioperative injury to a macroscopically intact recurrent laryngeal nerve (RLN), there are two possible intraneural injury types: 1) axonal injury, including disruption of axons, and 2) conduction block, only affecting the Schwann cells and the nodes of Ranvier. In this study, it was hypothesized that the functional outcome after RLN injury may depend on the type of nerve injury.
METHODS: Fifteen patients with acute postoperative unilateral RLN paralysis were prospectively studied. Electrophysiological examination (laryngeal electromyography) was used to differentiate between the two types of nerve injury. Vocal fold motions were monitored by repeated laryngoscopy during the study period (up to 6 months). Three of the patients with axonal injury were treated with the regeneration-promoting agent nimodipine.
RESULTS: The patients with conduction block all recovered normal vocal fold motion, whereas patients with axonal injury within the nerve had a significantly worse outcome. The 3 patients who were treated with nimodipine all recovered normal or near-normal vocal fold mobility despite the more severe axonal injury.
CONCLUSIONS: In contrast to previous reports, our results show that laryngeal electromyography is a reliable tool for diagnosing the type of injury within the injured RLN, making it possible to predict the functional outcome in these patients. On the basis of the results, a future randomized study on nimodipine treatment for RLN axonal injury is suggested.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708490     DOI: 10.1177/000348940911800709

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  8 in total

Review 1.  Recovery of laryngeal function after intraoperative injury to the recurrent laryngeal nerve.

Authors:  Per Mattsson; Jonas Hydman; Mikael Svensson
Journal:  Gland Surg       Date:  2015-02

Review 2.  Narrative review of proving the causal link of recurrent laryngeal nerve injury and thyroidectomy: a medico legal appraisal.

Authors:  Patrizia Gualniera; Serena Scurria; Cristina Mondello; Alessio Asmundo; Daniela Sapienza; Dionigi Gianlorenzo
Journal:  Gland Surg       Date:  2020-10

Review 3.  A narrative review of current therapies in unilateral recurrent laryngeal nerve injury caused by thyroid surgery.

Authors:  Hedi Tian; Jun Pan; Linghui Chen; Yijun Wu
Journal:  Gland Surg       Date:  2022-01

4.  A novel electrodiagnostic assessment of the laryngeal closure reflex.

Authors:  Bridget Carey; Lucian Sulica; Anita Wu; Ryan Branski
Journal:  Muscle Nerve       Date:  2013-02-04       Impact factor: 3.217

5.  Framework Surgery for Treatment of Unilateral Vocal Fold Paralysis.

Authors:  James J Daniero; C Gaelyn Garrett; David O Francis
Journal:  Curr Otorhinolaryngol Rep       Date:  2014-06-01

Review 6.  [Rehabilitation of facial palsy and vertigo in patients with vestibular schwannoma].

Authors:  B Müller; G F Volk; O Guntinas-Lichius
Journal:  HNO       Date:  2017-09       Impact factor: 1.284

7.  Prognostic Indicators of Non-Transection Nerve Injury and Vocal Fold Motion Impairment After Thyroid Surgery - Correlation Between Intraoperative Neuromonitoring Findings and Perioperative Voice Parameters.

Authors:  Tzu-Yen Huang; Wing-Hei Viola Yu; Feng-Yu Chiang; Che-Wei Wu; Shih-Chen Fu; An-Shun Tai; Yi-Chu Lin; Hsin-Yi Tseng; Ka-Wo Lee; Sheng-Hsuan Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-30       Impact factor: 5.555

Review 8.  Selective Electrical Surface Stimulation to Support Functional Recovery in the Early Phase After Unilateral Acute Facial Nerve or Vocal Fold Paralysis.

Authors:  Annabella Kurz; Gerd Fabian Volk; Dirk Arnold; Berit Schneider-Stickler; Winfried Mayr; Orlando Guntinas-Lichius
Journal:  Front Neurol       Date:  2022-04-04       Impact factor: 4.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.